Authors: Sarah Moussa ¹, Maya Tong², Marie-Claude Robert², Mona Harissi-Dagher², Sajjad Ahmad³, Samir Jabbour².  ¹McGill University, ²University of Montréal, ³Moorfields Eye Hospital.

Author Disclosures: S. Moussa:  None.  M. Tong:   None.  M. Robert:  None.   M. Harissi-Dagher:  None.  S. Ahmad:   None.  S. Jabbour:  None.

Abstract Body: 

Purpose:  To evaluate preferred diagnostic tools and treatment decision-making factors in cases suspicious of mucous membrane pemphigoid (MMP) amongst ophthalmologists and cornea specialists.  

Study Design:  Cross sectional survey  

Methods:   Web-based survey, consisting of 14 multiple choice questions, posted to the Cornea Society Listserv Keranet, the Canadian Ophthalmological Society Cornea Listserv and the Bowman club Listserv.   

Results:  One hundred and thirty-six ophthalmologists participated in the survey. Eighty six percent (86%) of respondents were cornea trained and practiced in either North America or Europe (83%). Most respondents (72%) routinely perform conjunctival biopsies for all suspicious cases of MMP. For those who do not, fear that biopsy will exacerbate inflammation was the most common reason to defer investigation (47%). Seventy one percent (71%) performed biopsies from perilesional sites. Ninety seven percent (97%) ask for direct (DIF) studies, and 60% for histopathology in formalin. Most do not recommend biopsy at other non-ocular sites (75%), nor do they perform indirect immunofluorescence for serum autoantibodies (68%). Immune-modulatory therapy is started following positive biopsy results for most (66%), albeit most (62%) would not let a negative DIF influence the choice of starting treatment should there be clinical suspicion of MMP.  

Conclusions:  Responses to the survey suggest that there is heterogeneity in certain practice patterns for MMP. Biopsy remains an area of controversy in dictating treatment plans. Identified areas of need should be targeted in future research.